

THSTI, Dabur to develop therapeutics for NAFLD

01 February 2019 | News

This is an Academia-Industry collaboration, in tune with joint efforts of DBT with AYUSH for herbal extraction based therapeutic development.



The Translational Health Science and Technology Institute (THSTI), an autonomous institute of Department of Biotechnology (DBT), has signed a Memorandum of Understanding (MoU) with Dabur India Ltd for joint development of herbal extracts as therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD).

Dabur is a global leader in herbal extract-based healthcare business. THSTI has strong expertise in Drug Discovery and Development. Both the collaborators bring complementary skills for Herbal Extract based drug discovery & development. This is an Academia-Industry collaboration, in tune with joint efforts of DBT with AYUSH for herbal extraction based therapeutic development.

The MoU was signed in the presence of officials from both THSTI and Dabur India Ltd. including Prof. Gagandeep Kang (Executive Director) and Dr. Madhu Dikshit (THSTI National Chair).